Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CAPR Capricor Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CAPR
Price (delayed)
$9.44
Market cap
$431.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.37
Enterprise value
$403.94M
Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead
Highlights
The debt has declined by 38% year-on-year and by 14% since the previous quarter
Capricor Therapeutics's net income has shrunk by 126% YoY and by 36% QoQ
The EPS has dropped by 65% year-on-year and by 19% since the previous quarter
Key stats
What are the main financial stats of CAPR
Market
Valuations
Earnings
Shares outstanding
45.71M
Market cap
$431.48M
Enterprise value
$403.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.38
Price to sales (P/S)
24.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.26
Revenue
$17.36M
Gross profit
$17.36M
Operating income
-$57.28M
Net income
-$55.06M
EBIT
-$55.06M
EBITDA
-$53.57M
Free cash flow
-$47.18M
Per share
Balance sheet
Liquidity
EPS
-$1.37
EPS diluted
-$1.37
Free cash flow per share
-$1.03
Book value per share
$2.79
Revenue per share
$0.38
TBVPS
$3.37
Total assets
$153.77M
Total liabilities
$26.12M
Debt
$1.25M
Equity
$127.65M
Working capital
$123.91M
Debt to equity
0.01
Current ratio
6.55
Quick ratio
6.48
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-308.5%
Gross margin
100%
Net margin
-317.1%
Operating margin
-329.9%
Return on assets
-48.4%
Return on equity
-62.4%
Return on invested capital
-85.9%
Return on capital employed
-41.9%
Return on sales
-317.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CAPR stock price
How has the Capricor Therapeutics stock price performed over time
Intraday
-1.26%
1 week
48.9%
1 month
-2.07%
1 year
67.38%
YTD
-31.59%
QTD
-0.53%
Financial performance
How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$17.36M
Gross profit
$17.36M
Operating income
-$57.28M
Net income
-$55.06M
Gross margin
100%
Net margin
-317.1%
Capricor Therapeutics's net income has shrunk by 126% YoY and by 36% QoQ
The operating income has dropped by 119% year-on-year and by 35% since the previous quarter
The net margin has dropped by 75% since the previous quarter
The company's operating margin has shrunk by 73% QoQ
Price vs fundamentals
How does CAPR's price correlate with its fundamentals
Growth
What is Capricor Therapeutics's growth rate over time
Valuation
What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
3.38
P/S
24.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.26
The EPS has dropped by 65% year-on-year and by 19% since the previous quarter
CAPR's P/B is 58% lower than its 5-year quarterly average of 8.0 and 52% lower than its last 4 quarters average of 7.0
CAPR's equity is down by 12% since the previous quarter
The price to sales (P/S) is 83% less than the 5-year quarterly average of 144.7 but 34% more than the last 4 quarters average of 18.5
CAPR's revenue is down by 36% year-on-year and by 22% since the previous quarter
Efficiency
How efficient is Capricor Therapeutics business performance
The ROS has dropped by 75% since the previous quarter
The ROE has soared by 73% YoY and by 6% QoQ
CAPR's ROIC has soared by 69% YoY and by 9% from the previous quarter
The ROA has decreased by 5% QoQ but it has increased by 4.7% YoY
Dividends
What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CAPR.
Financial health
How did Capricor Therapeutics financials performed over time
The current ratio has declined by 16% since the previous quarter
CAPR's quick ratio is down by 16% QoQ
The debt is 99% smaller than the equity
The debt to equity has plunged by 91% YoY
The debt has declined by 38% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.